BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 33740268)

  • 21. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
    Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
    Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States.
    Delea TE; Zhang X; Amdahl J; Boyko D; Dirnberger F; Campioni M; Cong Z
    Pharmacoeconomics; 2019 Sep; 37(9):1177-1193. PubMed ID: 31218655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytogenetic guided therapy using blinatumomab and inotuzumab ozogamicin in a patient with relapse/refractory acute lymphoblastic leukemia.
    Ohana Z; Serraes S; Elder C; Katusa N
    J Oncol Pharm Pract; 2022 Jul; 28(5):1269-1275. PubMed ID: 35043731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.
    Kantarjian HM; DeAngelo DJ; Advani AS; Stelljes M; Kebriaei P; Cassaday RD; Merchant AA; Fujishima N; Uchida T; Calbacho M; Ejduk AA; O'Brien SM; Jabbour EJ; Zhang H; Sleight BJ; Vandendries ER; Marks DI
    Lancet Haematol; 2017 Aug; 4(8):e387-e398. PubMed ID: 28687420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab.
    Short NJ; Macaron W; Konopleva M; Ravandi F; Jain N; Issa GC; Kadia T; Sasaki K; Kebriaei P; Yilmaz M; Thompson PA; Takahashi K; Abbas HA; Wierda WG; Garris R; Kantarjian HM; Jabbour E
    Am J Hematol; 2022 Jun; 97(6):E201-E204. PubMed ID: 35266566
    [No Abstract]   [Full Text] [Related]  

  • 26. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial.
    Jabbour E; Short NJ; Jain N; Thompson PA; Kadia TM; Ferrajoli A; Huang X; Yilmaz M; Alvarado Y; Patel KP; Garcia-Manero G; Macaron W; Garris R; Konopleva M; Ravandi F; Kantarjian H
    Lancet Haematol; 2022 Dec; 9(12):e878-e885. PubMed ID: 36279879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab.
    Wudhikarn K; King AC; Geyer MB; Roshal M; Bernal Y; Gyurkocza B; Perales MA; Park JH
    Blood Adv; 2022 Mar; 6(5):1432-1443. PubMed ID: 35042232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Liu L; Jiao W; Zhang Y; Qu Q; Li X; Wu D
    Leuk Res; 2015 Mar; 39(3):323-8. PubMed ID: 25638269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
    Stock W; Martinelli G; Stelljes M; DeAngelo DJ; Gökbuget N; Advani AS; O'Brien S; Liedtke M; Merchant AA; Cassaday RD; Wang T; Zhang H; Vandendries E; Jabbour E; Marks DI; Kantarjian HM
    Cancer; 2021 Mar; 127(6):905-913. PubMed ID: 33231879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL.
    Stelljes M; Raffel S; Alakel N; Wäsch R; Kondakci M; Scholl S; Rank A; Hänel M; Spriewald B; Hanoun M; Martin S; Schwab K; Serve H; Reiser L; Knaden J; Pfeifer H; Marx J; Sauer T; Berdel WE; Lenz G; Brüggemann M; Gökbuget N; Wethmar K
    J Clin Oncol; 2024 Jan; 42(3):273-282. PubMed ID: 37883727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
    Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Lee S
    Cancer Med; 2019 Dec; 8(18):7650-7659. PubMed ID: 31691536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic Leukemia.
    Senapati J; Kantarjian H; Haddad FG; Short NJ; Welch MA; Jain N; Jabbour E
    Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):333-339. PubMed ID: 38195323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world treatment patterns of novel drugs in relapsed or refractory acute lymphoblastic leukemia patients in Japan.
    Moribe T; Xu L; Tajima K; Yonemoto N
    Future Oncol; 2023 Jun; 19(19):1343-1356. PubMed ID: 37212792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
    Topp MS; Gökbuget N; Zugmaier G; Stein AS; Dombret H; Chen Y; Ribera JM; Bargou RC; Horst HA; Kantarjian HM
    Cancer; 2021 Feb; 127(4):554-559. PubMed ID: 33141929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ueda T; Fukushima K; Kusakabe S; Yoshida K; Suga M; Nakai R; Koike M; Hino A; Akuta K; Toda J; Nagate Y; Doi Y; Fujita J; Yokota T; Hosen N
    Leuk Res Rep; 2022; 17():100294. PubMed ID: 35242526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Salvage therapy for children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Kodama Y; Manabe A; Kawasaki H; Kato I; Kato K; Sato A; Matsumoto K; Kato M; Hiramatsu H; Sano H; Kaneko T; Oda M; Saito AM; Adachi S; Horibe K; Mizutani S; Ishii E; Shimada H
    Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28084041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
    Kantarjian HM; DeAngelo DJ; Stelljes M; Liedtke M; Stock W; Gökbuget N; O'Brien SM; Jabbour E; Wang T; Liang White J; Sleight B; Vandendries E; Advani AS
    Cancer; 2019 Jul; 125(14):2474-2487. PubMed ID: 30920645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study.
    Martinelli G; Boissel N; Chevallier P; Ottmann O; Gökbuget N; Rambaldi A; Ritchie EK; Papayannidis C; Tuglus CA; Morris JD; Stein A
    Eur J Cancer; 2021 Mar; 146():107-114. PubMed ID: 33588145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.
    Marks DI; Kebriaei P; Stelljes M; Gökbuget N; Kantarjian H; Advani AS; Merchant A; Stock W; Cassaday RD; Wang T; Zhang H; Loberiza F; Vandendries E; DeAngelo DJ
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1720-1729. PubMed ID: 31039409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia responding to retreatment with inotuzumab ozogamicin].
    Hashimoto H; Tamura Y; Yamada K; Katoh Y; Shimada T; Fujiwara R; Hanamoto H
    Rinsho Ketsueki; 2023; 64(8):746-750. PubMed ID: 37673626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.